Medication adherence and the patient with coronary artery disease: Challenges for the practitioner

Current Opinion in Cardiology

Volumn 24, Issue 5, 2009, Pages 468-472

  Maddox, Thomas M ^a,b   Ho, P Michael ^a,b  

^a VA Eastern Colorado Health Care System   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Adherence; Coronary artery disease; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ALCOHOL ABUSE; ATHEROSCLEROSIS; BEHAVIOR; CARDIAC PATIENT; CARDIOVASCULAR RISK; CAREGIVER BURDEN; COMORBIDITY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DRUG COST; DRUG USE; HEALTH CARE SYSTEM; HEALTH MAINTENANCE ORGANIZATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOWEST INCOME GROUP; MORTALITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT IDENTIFICATION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PUBLIC OPINION; REVIEW; SECONDARY PREVENTION; SOCIAL NETWORK; SOCIOECONOMICS; TREATMENT OUTCOME; TREATMENT REFUSAL; DISEASE COURSE; DRUG COMBINATION; DRUG EFFECTS; DYSLIPIDEMIAS; MEDICATION COMPLIANCE; RISK FACTOR; RISK REDUCTION; UNITED STATES;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MEDICATION ADHERENCE; MYOCARDIAL INFARCTION; RISK FACTORS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; UNITED STATES;

EID: 69749091980     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32832ed62d     Document Type: Review

References (27)

1. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: summary article - a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149-158.
2. Ho PM, Magid DJ, Masoudi FA, et al. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 2006; 6:48.
3. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113:203-212. (Pubitemid 43754376)
4. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288:455-461. (Pubitemid 34787476)
5. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27:1153-1158. (Pubitemid 43752385)
6. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008; 155:772-779. An important study linking nonadherence with cardiac-specific adverse outcomes.
7. Bissonnette JM. Adherence: a concept analysis. J Adv Nurs 2008; 63:634-643.
8. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11:44-47. (Pubitemid 351160875)
9. Choudhry NK, Setoguchi S, Levin R, et al. Trends in adherence to secondary prevention medications in elderly postmyocardial infarction patients. Pharmacoepidemiol Drug Saf 2008; 17:1189-1196.
10. Austin PC, Tu JV, Ko DT, Alter DA. Use of evidence-based therapies after discharge among elderly patients with acute myocardial infarction. CMAJ 2008; 179:895-900.
11. Al-Omran M, Mamdani MM, Lindsay TF, et al. Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study. J Vasc Surg 2008; 48:607-612.
12. Amar J, Ferrieres J, Cambou JP, et al. Persistence of combination of evidence-based medical therapy in patients with acute coronary syndromes. Arch Cardiovasc Dis 2008; 101:301-306.
13. Foody JM, Joyce AT, Rudolph AE, et al. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr Med Res Opin 2008; 24:1987-2000.
14. Turley AJ, Roberts AP, Morley R, et al. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up. Interact Cardiovasc Thorac Surg 2008; 7:231-234.
15. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30:2167-2179.
16. Setoguchi S, Glynn RJ, Avorn J, et al. Improvements in long-termmortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol 2008; 51:1247-1254. A large study demonstrating the importance of secondary prevention medication use in reducing all-cause mortality rates over time.
17. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008; 117:1028-1036. This article takes a comprehensive look at medication adherence rates and associated factors in a large Canadian cohort.
18. Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 2008; 14:271-280. (Pubitemid 351711978)
19. Khanderia U, Townsend KA, Erickson SR, et al. Medication adherence following coronary artery bypass graft surgery: assessment of beliefs and attitudes. Ann Pharmacother 2008; 42:192-199. (Pubitemid 351238566)
20. Molloy GJ, Perkins-Porras L, Strike PC, Steptoe A. Social networks and partner stress as predictors of adherence to medication, rehabilitation attendance, and quality of life following acute coronary syndrome. Health Psychol 2008; 27:52-58. (Pubitemid 351215347)
21. Kripalani S, Henderson LE, Jacobson TA, Vaccarino V. Medication use among inner-city patients after hospital discharge: patient-reported barriers and solutions. Mayo Clin Proc 2008; 83:529-535. (Pubitemid 351716999)
22. Reaume KT, Erickson SR, Dorsch MP, et al. Effects of cerivastatin withdrawal on statin persistence. Ann Pharmacother 2008; 42:956-961.
23. Bryson CL, Au DH, Sun H, et al. Alcohol screening scores and medication nonadherence. Ann Intern Med 2008; 149:795-804.
24. Daugherty SL, Ho PM, Spertus JA, et al. Association of early follow-up after acute myocardial infarction with higher rates of medication use. Arch Intern Med 2008; 168:485-491.
25. Wood DA, Kotseva K, Connolly S, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008; 371:1999-2012.
26. Smith DH, Kramer JM, Perrin N, et al. A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. Arch Intern Med 2008; 168:477-483. (Pubitemid 351547210)
27. Choudhry NK, Brennan T, Toscano M, et al. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for postmyocardial infarction secondary preventive therapies. Am Heart J 2008; 156:31-36.